Impact of CD33 and ABCB1 single nucleotide polymorphisms in patients with acute myeloid leukemia and advanced myeloid malignancies treated with decitabine plus gemtuzumab ozogamicin

Am J Hematol. 2020 Sep;95(9):E225-E228. doi: 10.1002/ajh.25854. Epub 2020 May 23.

Authors

Affiliations

¹ Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
² Department of Hematopathology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
³ Department of Pharmacotherapy & Translational Research, The University of Florida, Gainesville, Florida, USA.

PMID: 32356320
DOI: 10.1002/ajh.25854

No abstract available

Publication types

Letter
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't

MeSH terms

ATP Binding Cassette Transporter, Subfamily B / genetics
Adult
Antineoplastic Combined Chemotherapy Protocols / administration & dosage*
Decitabine / administration & dosage
Female
Gemtuzumab / administration & dosage
Hematologic Neoplasms* / drug therapy
Hematologic Neoplasms* / genetics
Hematologic Neoplasms* / mortality
Humans
Leukemia, Myeloid, Acute* / drug therapy
Leukemia, Myeloid, Acute* / genetics
Leukemia, Myeloid, Acute* / mortality
Male
Neoplasm Proteins / genetics*
Polymorphism, Single Nucleotide*
Sialic Acid Binding Ig-like Lectin 3 / genetics*

Substances

ABCB1 protein, human
ATP Binding Cassette Transporter, Subfamily B
CD33 protein, human
Neoplasm Proteins
Sialic Acid Binding Ig-like Lectin 3
Decitabine
Gemtuzumab

Grants and funding